Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients

Authors:	Marius Ilie MD PhD Jonathan Juco MD Lingkang Huang PhD Veronique Hofman MD PhD Shirin Khambata‐Ford PhD Paul Hofman MD PhD

Affiliation:	1. Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge, C?te d'Azur University, Nice, France;2. Institute for Research on Cancer and Aging in Nice (National Institute of Health and Medical Research Unit 1081 and National Center of Scientific Research Joint Research Unit 7284), C?te d'Azur University, Nice, France;3. Hospital‐Integrated Biobank (BB‐0033‐00025), Pasteur Hospital, C?te d'Azur University, Nice, France;4. Merck & Co, Inc, Kenilworth, New Jersey

Abstract:

Keywords:	biomarker cytology immunohistochemistry non– small cell lung cancer programmed death‐ligand 1